During this transition, customers may receive inventory labeled as either the GLP-1 Support Patch or the Berberine Patch while packaging updates are completed
However, this does not mean your face will permanently look as severe as it does at the peak of your weight loss
It belongs to the GLP-1 class but represents the third generation of that class
The expected timeline: Phase 3 trials completing: Results rolling out throughout the rest of this year FDA submission: Expected sometime after full Phase 3 data is available Potential FDA approval: Estimated for late 2027 at the earliest Commercial availability: If approved, launch would follow in 2027-2028 For those tracking retatrutide availability updates , the situation is evolving
Participants who reported food tasting sweeter after taking GLP-1s were twice as likely to report increased satiety, 67% more likely to report a reduction in appetite, and 85% more likely to report a reduction in food cravings
Follow your clinicians guidance during dose adjustments
